Literature DB >> 2886883

EC array sensor concepts and data.

W R Matson, P G Gamache, M F Beal, E D Bird.   

Abstract

The use of multiple parameter assays of entire metabolic pathways is potentially a powerful tool for unraveling mechanisms of disorders or drug action and classification of neurological diseases. Coulometric electrode series array sensors, coupled with liquid chromatography (n-ELC), provide a route to multiplying the resolving power of conventional LC by factors of 10 to 50. Since the original description of the n-ELC concept by Matson et al. (1), fundamental issues of optimizing sensor design and integration with computer controlled LC systems have been addressed. Femtogram level potential time (ET) separations can now be performed for multiple components in both isocratic and gradient modes. A 56-component isocratic method for the study of the kynurenine system in Huntington's Disease (HD) is presented as an indication of the analytical definitions and nomenclature used to qualify an n-ELC procedure, and an indication of the implications of multiparameter data bases on data handling and experimental design.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2886883     DOI: 10.1016/0024-3205(87)90192-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  11 in total

1.  Identifying monoaminergic, GABAergic, and cholinergic characteristics in immortalized neuronal cell lines.

Authors:  F Gallyas; J Satoh; A M Takeuchi; Y Konishi; T Kunishita; T Tabira
Journal:  Neurochem Res       Date:  1997-05       Impact factor: 3.996

2.  Neuropsychological profile linked to low dopamine: in Alzheimer's disease, major depression, and Parkinson's disease.

Authors:  N Wolfe; D I Katz; M L Albert; A Almozlino; R Durso; M C Smith; L Volicer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-10       Impact factor: 10.154

3.  CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease.

Authors:  Peter LeWitt; Lonni Schultz; Peggy Auinger; Mei Lu
Journal:  Brain Res       Date:  2011-07-01       Impact factor: 3.252

4.  Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease.

Authors:  J A Wolff; L J Fisher; L Xu; H A Jinnah; P J Langlais; P M Iuvone; K L O'Malley; M B Rosenberg; S Shimohama; T Friedmann
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

Review 5.  Metabolic investigation in psychiatric disorders.

Authors:  Jeffrey K Yao; Ravinder D Reddy
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

6.  Independent effects of cholinergic and serotonergic lesions on acetylcholine and serotonin release in the neocortex of the rat.

Authors:  A J Dekker; L J Thal
Journal:  Neurochem Res       Date:  1993-03       Impact factor: 3.996

7.  Long-term increases in neurotransmitter release from neuronal cells expressing a constitutively active adenylate cyclase from a herpes simplex virus type 1 vector.

Authors:  A I Geller; M J During; J W Haycock; A Freese; R Neve
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

8.  An HSV-1 vector expressing tyrosine hydroxylase causes production and release of L-dopa from cultured rat striatal cells.

Authors:  A I Geller; M J During; Y J Oh; A Freese; K O'Malley
Journal:  J Neurochem       Date:  1995-02       Impact factor: 5.372

9.  8OHdG as a marker for Huntington disease progression.

Authors:  Jeffrey D Long; Wayne R Matson; Andrew R Juhl; Blair R Leavitt; Jane S Paulsen
Journal:  Neurobiol Dis       Date:  2012-03-05       Impact factor: 5.996

10.  8OHdG is not a biomarker for Huntington disease state or progression.

Authors:  Beth Borowsky; John Warner; Blair R Leavitt; Sarah J Tabrizi; Raymund A C Roos; Alexandra Durr; Chris Becker; Cristina Sampaio; Allan J Tobin; Howard Schulman
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.